In addition, in a phase I study in which the anti-PD-L1 antibody MPDL3280A was administered to 20 subjects, 1 CRC patient with deletion of a mismatch repair (MMR) gene exhibited a partial response [49]. This evidence concerns the gene CD274 and colorectal carcinoma.